MAPT and Alzheimer disease: Currently, it is anticipated that globally, beyond 40 million people are suffering from Alzheimer’s disease (AD).1 With a continuously aging population, the incident rate of AD is anticipated to rise substantially.2 AD is a progressive disorder caused by neuron impairment in the hippocampus, accumulation of amyloid plaques, hyperphosphorylated tau protein, and neurofibrillary tangles (NFTs).